[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"randomised-clinical-trial\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:randomised-clinical-trial":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100612664","comparative-evaluation-of-finger-splint-paraffin-and-peloidotherapy-interventions-in-the-management-of-trigger-finger-100612664",false,"NCT07256522","Comparative Evaluation of Finger Splint, Paraffin, and Peloidotherapy Interventions in the Management of Trigger Finger","Comparative Evaluation of Finger Splint, Paraffin, and Peloidotherapy Interventions in the Management of Trigger Finger. A Prospective, Randomized, Controlled Study","Inclusion Criteria:\n\n* Being between 18 and 75 years of age and willing to participate in the study\n* Having a diagnosis of idiopathic single trigger finger, Grade 2-3\n\nExclusion Criteria:\n\n* Patients with triggering in more than one finger\n* Patients with triggering at the A3 pulley or with Grade 1 or Grade 4 trigger finger\n* Patients with thumb (pollex) trigger finger\n* Patients who have undergone any injection or interventional procedure (release surgery) for trigger finger within the past 6 months\n* Patients who have received physical therapy for the hand within the past 6 months\n* Patients currently using corticosteroids or nonsteroidal anti-inflammatory drugs (NSAIDs)\n* Patients with inflammatory or autoimmune rheumatologic diseases such as rheumatoid arthritis, systemic lupus erythematosus, gout, or psoriatic arthritis\n* Patients with other musculoskeletal disorders (e.g., carpal tunnel syndrome, de Quervain's tenosynovitis, symptomatic hand osteoarthritis, or Dupuytren's contracture) or neurological diseases (e.g., stroke-related hemiparesis, spinal cord injury, brachial plexus injury, multiple sclerosis, or Parkinsonism) affecting the same hand\n* Patients with musculoskeletal disorders causing pain and\u002For limitation in the proximal upper extremity on the affected side (e.g., periarthritis, lateral epicondylitis, mononeuropathy, or radiculopathy)\n* Patients with significant metabolic diseases (e.g., hypothyroidism, Cushing's syndrome, or uncontrolled diabetes)\n* Patients with any condition that may interfere with treatment, such as open wounds, rashes, local infections, or active malignant disease of the hand\n* Patients with a history of hand trauma (chronic or repetitive)\n* Patients unwilling to complete the self-assessment questionnaires either independently or with assistance\n* Pregnant women","ALL","18 Years","75 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","Patients aged 18-75 years who present with trigger finger to a tertiary rehabilitation hospital and agree to participate will be included in the study. Participants will be randomly allocated into three groups using block randomization. The first group will use a static finger splint that blocks the proximal interphalangeal joint for 6 weeks, along with a home exercise program. The second group will receive paraffin bath therapy, and the third group will receive peloidotherapy, both in combination with home exercises.\n\nAll patients will receive education about the disease and activity modification. The finger joint-restricting splint and exercises will be applied for 6 weeks. Evaluations will be conducted at baseline, at the end of the 3rd week, and at the end of the 6th week by a blinded assessor. No analgesic or anti-inflammatory medication will be permitted during the study, and patients will be instructed to avoid using analgesics within 24 hours prior to each assessment.",[27,28,29,30,31,32],"Trigger Finger","Splint Therapy","Paraffin Bath","Peloidotherapy","Efficacy and Safety","Randomised Clinical Trial",[34,35,36,37,38],"trigger finger","splint therapy","paraffin bath","peloidotherapy","Randomised Controlled Study","RECRUITING","2026-03-17",{"date":42,"type":43},"2026-03-19","ACTUAL",{"date":45,"type":43},"2025-12-15",{"date":47,"type":21},"2027-02-15",{"name":49,"class":50},"Konya Beyhekim Training and Research Hospital","OTHER_GOV",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":60,"minAge":17,"maxAge":18,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":64,"conditions":65,"keywords":71,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":51},"100593781","platelet-rich-plasma-injections-from-cord-blood--penile-traction-vs-penile-traction-alone-in-patients-with-peyronies-disease-open-label-single-center-randomized-study-100593781","NCT07010900","Platelet-Rich Plasma Injections From Cord Blood + Penile Traction vs. Penile Traction Alone in Patients With Peyronie's Disease. Open-label, Single-center Randomized Study","Platelet-Rich Plasma Injections From Cord Blood + Penile Traction vs. Penile Traction Alone in Patients With Peyronie's Disease.","CB-PRP-TRAC1","Inclusion Criteria:\n\n* Patients with Peyronie's Disease (IPP) Penile curvature greater than 30 degrees (autophotography in erection with goniometer measurement) Patients candidates for penile traction Age: 18-75 years Good health conditions Preserved erection (IIEF \\>20) Complete blood count with differential and coagulation within the normal range (platelets between 150,000 and 450,000 μL) HIV, HCV, and HbsAg negative The fertile partner of the patient randomized to the experimental group must use an acceptable highly effective contraceptive method (oral contraceptives, intrauterine device, abstinence, vasectomized partner) for the entire duration of the study Informed consent to the study\n\nExclusion Criteria:\n\nCoagulopathies, platelet disorders Major active infections Previous penile surgery (excluding circumcision and condyloma removal) Previous infiltrative therapy or penile traction treatment","MALE",{"count":62,"type":21},42,[24],"The goal of this clinical trial is to learn if Platelet-Rich Plasma Injections from Cord Blood (CB-PRP) is useful in Peyronie disease.\n\nThe primary goal is evaluation of patient satisfaction at 1 and 3 months after treatment completion using the PDQ Questionnaire\n\nSecondary Objectives are:\n\n* Measurement of penile curvature measured with a goniometer with spontaneous erection before and after treatment (1 and 3 months)\n* Measurement of penile length in stretching before and after treatment (1 and 3 months)\n* Evaluation of the improvement in quality of life, through the Short-Form Health Survey 12 (SF-12) health status questionnaire and through the Hospital Anxiety and Depression Scale (HADS)\n\nParticipants will be randomized in two groups:\n\n* penile extender alone\n* penile extender + CB PRP injection (1 injection every 15 days - 3 in totalinjections)",[66,67,68,69,32,70],"Peyronie Disease","Penile Curvature","PRP Injection","Cord Blood","Penile Injection Therapy",[72,73,74,75],"penile exteder","peyronie disease","prp","cord blood prp","2025-05-30",{"date":78,"type":43},"2025-06-08",{"date":80,"type":21},"2025-05-28",{"date":82,"type":21},"2026-12-31",{"name":84,"class":85},"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","OTHER"]